Last reviewed: 4 Jul 2021
Last updated: 17 Dec 2020

Summary

Definition

History and exam

Key diagnostic factors

  • movement of one side of the body or one specific body part
  • premonitory sensation or experience (fear, epigastric sensation, déjà vu, jamais vu)
  • automatisms (picking at clothes, smacking of the lips)
  • temporary aphasia
  • staring and being unaware of surroundings

Other diagnostic factors

  • postictal focal neurological deficit (Todd paralysis, aphasia)
  • persistent focal neurological deficit
  • poor memory
  • stigmata of neurocutaneous syndromes

Risk factors

  • febrile seizure
  • traumatic brain injury
  • central nervous system (CNS) infection
  • stroke
  • brain tumor
  • intellectual disability and/or cerebral palsy
  • dementia
  • family history of seizures
  • vascular malformations
  • male sex

Diagnostic investigations

1st investigations to order

  • blood glucose
  • CBC
  • electrolyte panel
  • toxicology screen
  • lumbar puncture and cerebrospinal fluid analysis
  • CT head
  • MRI brain
  • electroencephalogram (EEG)

Investigations to consider

  • video/electroencephalogram (EEG) long-term monitoring (LTM)
  • PET scan
  • single photon emission computed tomography (SPECT) scan
  • functional MRI scan
  • magnetoencephalography (MEG) scan
  • neuropsychological testing
  • Wada test

Treatment algorithm

Contributors

Authors

Ramses Ribot, MD

Assistant Professor of Clinical Neurology

Department of Neurology, Epilepsy Division

University of Miami, Miller School of Medicine

Miami

FL

Disclosures

RR has received consultancy funds from Supernus Pharmaceuticals, Inc.

Andres M. Kanner, MD, FANA, FAES, FAAN

Professor of Clinical Neurology

Director, Comprehensive Epilepsy Center and Head, Section of Epilepsy

Department of Neurology

University of Miami, Miller School of Medicine

Miami

FL

Disclosures

AMK has received honoraria from Eisai laboratories and Neuropace. AMK is an author of a number of references cited in this topic.

Acknowledgements

Dr Ramses Ribot and Dr Andres M. Kanner would like to gratefully acknowledge Dr Vikram R. Rao, Dr John D. Hixson, and Dr Jeffrey Cohen, previous contributors to this topic.

Disclosures

VRR served as a paid consultant for Neuropace, Inc., manufacturer of the Responsive Neurostimulation (RNS) System. JDH has received research funding and consultancy funds from UCB, Inc. JC declares that he has no competing interests.

Peer reviewers

Edward Bromfield, MD

Chief

Epilepsy Division

Brigham and Women's Hospital

Associate Professor of Neurology

Harvard Medical School

Boston

MA

Disclosures

At the time of review, EB declared that between 2004 and 2009, he received speaking honoraria from UCB Pharma, Novartis, Abbott Laboratories, GlaxoSmithKline, and Pfizer. He received consulting fees from UCB Pharma, Genzyme, and Spherics, and research funding from UCB Pharma. Unfortunately, we have since been made aware that EB is deceased.

Angus A. Wilfong, MD

Associate Professor

Pediatrics and Neurology

Baylor College of Medicine

Medical Director

Comprehensive Epilepsy Program

Texas Children's Hospital

Houston

TX

Disclosures

AAW declares that he has no competing interests.

Cigdem I. Akman, MD

Assistant Professor

Division of Pediatric Neurology

Columbia University College of Physicians and Surgeons

New York

NY

Disclosures

Not disclosed.

Pasquale Striano, MD, PhD

Consultant Neurologist

Muscular and Neurodegenerative Diseases Unit

G Gaslini" Institute

Genova

Epilepsy Centre

Federico II University

Napoli

Italy

Disclosures

PS declares that he has no competing interests.

Use of this content is subject to our disclaimer